(NASDAQ: LYEL) Lyell Immunopharma's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 15.34%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 20.02%.
Lyell Immunopharma's earnings in 2024 is -$210,259,000.On average, 3 Wall Street analysts forecast LYEL's earnings for 2024 to be -$216,757,836, with the lowest LYEL earnings forecast at -$235,522,864, and the highest LYEL earnings forecast at -$199,682,428. On average, 3 Wall Street analysts forecast LYEL's earnings for 2025 to be -$230,402,802, with the lowest LYEL earnings forecast at -$271,363,300, and the highest LYEL earnings forecast at -$202,242,459.
In 2026, LYEL is forecast to generate -$199,682,428 in earnings, with the lowest earnings forecast at -$199,682,428 and the highest earnings forecast at -$199,682,428.